Intended for Healthcare Professionals
REVERSE-IT is a Phase 3 study for the reversal of the antiplatelet effects of ticagrelor with bentracimab
DOCUMENT LIBRARY
Access investigator resource library, including trial protocols & amendments, pharmacy manuals, regulatory templates source documents and more.
CLINICIAN VIGNETTES
Are you in cardiology, hematology or another specialized field? Access interviews with various clinicians whose practice could bring them in contact with patients who may warrant referral to the REVERSE-IT trial.
NEWSROOM
Stay up to date with the latest trial newsletters, webinars and press releases
BENTRACIMAB
A novel monoclonal antibody designed to reverse the antiplatelet activity of ticagrelor
ENROLLING PATIENTS
- Patients who present with uncontrolled major or life-threatening bleeding
- Patient who require urgent surgery or invasive procedure
STUDY SUMMARY
Approximately 200 patients will be enrolled from approximately 200 centers in North America, Europe, and Asia-Pacific regions, including mainland China. Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible for enrollment. These populations will be enrolled based on separate inclusion criteria.
STUDY LOCATIONS:
Please select a location to see sites near you